The Monoclonal Antibodies
Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the monoclonal antibodies partnering deals and agreements
entered into by the worlds leading healthcare companies.
The report provides a detailed
understanding and analysis of how and why companies enter monoclonal antibody
partnering deals. The majority of deals are development stage whereby the licensee
obtains a right or an option right to license the licensors monoclonal antibody
technology. These deals tend to be multicomponent, starting with collaborative
R&D, and commercialization of outcomes.
This report provides details of the
latest monoclonal antibody deals announced in the healthcare sectors.
Understanding the flexibility of a
prospective partner’s negotiated deals terms provides critical insight into the
negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of
the payments clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases and
databases do not.
This report contains a comprehensive
listing of all monoclonal antibody partnering deals announced since 2007
including financial terms where available including over 700 links to online
deal records of actual biomarker partnering deals as disclosed by the deal
parties. In addition, where available, records include contract documents as
submitted to the Securities Exchange Commission by companies and their
partners.
To Read The Complete Report with
TOC : http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-partnering-terms-and-agreements
Contract documents provide the
answers to numerous questions about a prospective partner’s flexibility on a
wide range of important issues, many of which will have a significant impact on
each party’s ability to derive value from the deal.
For example, analyzing actual
company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the
partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and
manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have
been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner
to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for
agreement law?
The initial chapters of this report
provide an orientation of monoclonal antibody dealmaking and business
activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in monoclonal antibody
dealmaking since 2007, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading monoclonal antibody deals
since 2007. Deals are listed by headline value and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link
provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma
companies with a brief summary followed by a comprehensive listing of
monoclonal antibody deals as well as contract documents available in the public
domain. Where available, each deal title links via Weblink to an online version
of the actual contract document, providing easy access to each contract
document on demand.
Chapter 5 provides a comprehensive listing of the top big biotech
companies with a brief summary followed by a comprehensive listing of
monoclonal antibody deals as well as contract documents available in the public
domain. Where available, each deal title links via Weblink to an online version
of the actual contract document, providing easy access to each contract
document on demand.
Chapter 6 provides a comprehensive and detailed review of monoclonal
antibody partnering deals signed and announced since January 2007, where a
contract document is available in the public domain. The chapter is organized
by stage of development at signing, deal type (collaborative R&D,
co-promotion, licensing etc), and specific therapy focus. Each deal title links
via Weblink to an online version of the deal record, providing easy access to
each contract document on demand.
Chapter 7 provides a comprehensive list and detailed review of
monoclonal antibody partnering deals signed and announced since January 2007,
by specific technology type. Where available, each deal title links via Weblink
to an online version of the actual contract document, providing easy access to
each contract document on demand.
In addition, a comprehensive
appendix is provided organized by monoclonal antibody partnering company A-Z,
deal type, stage of development and therapy type deals. Each deal title links
via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
In conclusion, this report provides
everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of biomarker technologies and
products.
Report scope
Monoclonal Antibodies Partnering
Terms & Agreements is intended to provide the reader with an in-depth
understanding and access to monoclonal antibodies trends and structure of deals
entered into by leading companies worldwide.
Monoclonal Antibodies Partnering
Terms & Agreements includes:
- Trends in monoclonal antibodies dealmaking in the
biopharma industry since 2007
- Analysis of monoclonal antibodies deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 700 monoclonal antibodies deal records
- The leading monoclonal antibodies deals by value since
2007
- Includes chimeric mAb, humanized mAb, human mAb and
murine mAb deals and alliances since 2007
In Monoclonal Antibodies Partnering
Terms & Agreements, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Monoclonal antibodies type
Each deal title links via Weblink to
an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
The Monoclonal Antibodies Partnering
Terms & Agreements report provides comprehensive access to available deals
and contract documents for over 700 monoclonal antibody deals.
To
Buy a Copy Of This Report: http://www.marketresearchreports.biz/analysis/168863
Analyzing actual contract agreements
allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the
partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and
manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have
been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner
to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for
agreement law?
About Us
MarketResearchReports.Biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment